Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial

Journal of Clinical Oncology

Volumn 24, Issue 25, 2006, Pages 4184-4189

  Otto, Suzie J ^a   Schröder, Fritz H ^a   De Koning, Harry J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUROPE; FOLLOW UP; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; ANALYSIS OF VARIANCE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RISK ASSESSMENT; RISK FACTOR;

AGED; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; COMORBIDITY; EUROPE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS;

EID: 33748636425     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4288     Document Type: Article

References (25)

1. Association of Comprehensive Cancer Centres: Cancer in the Netherlands, incidence and mortality. http://www.cancerregistry.nl
2. Sirovich BE, Schwartz LM, Woloshin S: Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence? JAMA 289:1414-1420, 2003
3. Melia J, Moss S, Johns L: Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: A cross-sectional study. BJU Int 94:51-56, 2004
4. de Koning HJ, Auvinen A, Berenguer Sanchez A, et al: Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 97:237-244, 2002
5. Prorok PC, Andriole GL, Bresalier RS, et al: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21:273S-309S, 2000
6. Holmberg L, Bill-Axelson A, Helgesen F, et al: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781-789, 2002
7. Satariano WA, Ragland KE, Van Den Eeden SK: Cause of death in men diagnosed with prostate carcinoma. Cancer 83:1180-1188, 1998
8. Post PN, Hansen BE, Kil PJ, et al: The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: A population-based study. BJU Int 87:821-826, 2001
9. Fouad MN, Mayo CP, Funkhouser EM, et al: Comorbidity independently predicted death in older prostate cancer patients, more of whom died with than from their disease. J Clin Epidemiol 57:721-729, 2004
10. Roobol MJ, Kirkels WJ, Schroder FH: Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 92:48-54, 2003 (suppl 2)
11. Beemsterboer PM, Kranse R, de Koning HJ, et al: Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 84:437-441, 1999
12. Statistics Netherlands: Statline. http://statline.cbs.nl/
13. Smith PH: The Data Monitoring Committee: Bridging the gap between urology and public health epidemiology. BJU Int 92:55-56, 2003 (suppl 2)
14. Breslow NE, Day NE: Statistical Methods in Cancer Research: The Design and Analysis of Cohort Studies. Lyon, France, IARC, 1987
15. Hankey BF, Feuer EJ, Clegg LX, et al: Cancer surveillance series: Interpreting trends in prostate cancer, part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91:1017-1024, 1999
16. Draisma G, Boer R, Otto SJ, et al: Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95:868-878, 2003
17. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al: Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 116:291-296, 2005
18. Lu-Yao GL, McLerran D, Wasson J, et al: An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes - The Prostate Patient Outcomes Research Team. JAMA 269:2633-2636, 1993
19. Dillioglugil O, Leibman BD, Leibman NS, et al: Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol 157:1760-1767, 1997
20. Begg CB, Riedel ER, Bach PB, et al: Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138-1144, 2002
21. Froehner M, Koch R, Litz R, et al: Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology 61:596-600, 2003
22. Alibhai SM, Leach M, Tomlinson G, et al: 30-day mortality and major complications after radical prostatectomy: Influence of age and comorbidity. J Natl Cancer Inst 97:1525-1532, 2005
23. Essink-Bot ML, de Koning HJ, Nijs HGT, et al: Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 90:925-931, 1998
24. Otto SJ, Schroder FH, de Koning HJ: Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: Self-selection bias? J Med Screen 11:89-92, 2004
25. Black WC, Haggstrom DA, Welch HG: All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94:167-173, 2002